KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Tax Provisions (2016 - 2025)

Charles River Laboratories International has reported Tax Provisions over the past 17 years, most recently at -$17.8 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 485.05% year-over-year to -$17.8 million; the TTM value through Dec 2025 reached $42.7 million, down 37.1%, while the annual FY2025 figure was $42.7 million, 37.1% down from the prior year.
  • Tax Provisions for Q4 2025 was -$17.8 million at Charles River Laboratories International, down from $31.6 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $55.8 million in Q4 2022 and troughed at -$17.8 million in Q4 2025.
  • A 5-year average of $21.2 million and a median of $24.2 million in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: skyrocketed 559.91% in 2022 and later plummeted 485.05% in 2025.
  • Year by year, Tax Provisions stood at $23.8 million in 2021, then skyrocketed by 134.37% to $55.8 million in 2022, then plummeted by 64.61% to $19.8 million in 2023, then crashed by 115.41% to -$3.0 million in 2024, then plummeted by 485.05% to -$17.8 million in 2025.
  • Business Quant data shows Tax Provisions for CRL at -$17.8 million in Q4 2025, $31.6 million in Q3 2025, and $18.7 million in Q2 2025.